Abstract:Objective: Chronic hypoxia causes pulmonary vasoconstriction leading to pulmonary hypertension and right ventricular hypertrophy. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis; its level increases in hypoxia (HX) concomitantly with reduced activity of dimethylarginine dimethylaminohydrolases (DDAH-1 and DDAH-2), enzymes metabolizing ADMA. Ddah1 knockout (KO) mice may therefore help to understand the pathophysiological roles of this enzyme and its substrate, ADMA, in the development of hypoxia-associated pulmonary hypertension. Methods: Ddah1 KO mice and their wild-type (WT) littermates were subjected to normoxia (NX) or for 21 days. We measured ADMA concentration in plasma and lungs, DDAH1 and DDAH2 mRNA and protein expression in the lungs, right ventricular systolic pressure (RVSP), right ventricular hypertrophy by the Fulton index, and cardiomyocyte hypertrophy by dystrophin staining of the heart. Results: Ddah1 KO mice had higher ADMA concentrations in plasma and in lung tissue than WT in NX (p < 0.05). ADMA significantly increased in WT-HX in plasma and lungs, while there were no significant differences in WT-HX vs. KO-HX. This finding was paralleled by a 38 ± 13% reduction in Ddah1 but not Ddah2 mRNA expression, and reduced DDAH1 protein expression but stable DDAH2 protein levels in WT mice. Ddah1 KO mice showed significant elevation of DDAH2 protein but not mRNA levels, which further increased in HX. HX led to increased RVSP and right ventricular hypertrophy in both, WT and KO mice, with no significant differences between both genotypes. Conclusions: Chronic hypoxia causes an elevation of ADMA, which may impair NO production and lead to endothelial dysfunction and vasoconstriction. Downregulation of DDAH1 expression and activity may be involved in this; however, knockout of the Ddah1 gene does not modify the hypoxia-induced pathophysiological changes of pulmonary blood pressure and right ventricular hypertrophy, possibly due to compensatory upregulation of DDAH2 protein.

Dimethylarginine Dimethylaminohydrolase-1 is the Critical Enzyme for Degrading the Cardiovascular Risk Factor Asymmetrical Dimethylarginine.

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

Vascular Endothelial-Specific Dimethylarginine Dimethylaminohydrolase-1–Deficient Mice Reveal That Vascular Endothelium Plays an Important Role in Removing Asymmetric Dimethylarginine

Cardiomyocyte Dimethylarginine Dimethylaminohydrolase-1 (DDAH1) Plays an Important Role in Attenuating Ventricular Hypertrophy and Dysfunction

Dimethylarginine Dimethylaminohydrolase and Cardiovascular Diseases

A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase

Asymmetric Dimethylarginine: A Novel Risk Factor for Cardiovascular Disease

Dimethylarginine Dimethylaminohydrolase 1 Modulates Endothelial Cell Growth Through Nitric Oxide and Akt

Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis

Redefining the biological and pathophysiological role of dimethylarginine dimethylaminohydrolase 2

Relations Between Plasma Asymmetric Dimethylarginine (adma) and Risk Factors for Coronary Disease

Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO.

Cardiomyocyte Dimethylarginine Dimethylaminohydrolase1 Attenuates Left-Ventricular Remodeling after Acute Myocardial Infarction: Involvement in Oxidative Stress and Apoptosis.

Dimethylarginine Dimethylaminohydrolase 1 Deficiency Aggravates Monocrotaline-Induced Pulmonary Oxidative Stress, Pulmonary Arterial Hypertension and Right Heart Failure in Rats.

Effect of Asymmetric Dimethylarginine (ADMA) on Heart Failure Development

Upregulation of DDAH2 Limits Pulmonary Hypertension and Right Ventricular Hypertrophy During Chronic Hypoxia in Ddah1 Knockout Mice

DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage

Ddah1 Deficiency Attenuates Endothelial Cell Cycle Progression and Angiogenesis

Repetitive Ischemia Increases Myocardial Dimethylarginine Dimethylaminohydrolase 1 Expression

Correlations of DDAH1 transcript variants with human endothelial asymmetric dimethylarginine metabolizing activity.

Levels of Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor, and Risk of Coronary Artery Disease: A Meta-Analysis Based on 4713 Participants.